VivoSeq
Other

T2DM

0

Pipeline Programs↗

4

Active Trials↗

5

Companies Involved↗

T2DM is an early-stage landscape with 0 programs across 5 companies. The most active players are Jiangsu Hansoh Pharmaceutical Co., Ltd., JW Pharmaceutical, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.

0 programs

PreclinicalJ

JW Pharmaceutical

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalE

Elcelyx Therapeutics, Inc.

0 programs

PreclinicalInnovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

18

clinical trials

Completed10 · 56%
Unknown status3 · 17%
Recruiting2 · 11%
Not yet recruiting2 · 11%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

18 trials

Effect of Mutations in T2DM Susceptibility Genes on the Expression of Susceptibility Genes in Patients With T2DM and Controls
Recruiting·TThe Affiliated Hospital of Xuzhou Medical University·N/A·NCT06277466·300 enrolled
Glycemic Variability of Combination Therapies in T2DM
Recruiting·JJW Pharmaceutical·Phase 4·NCT07442006·178 enrolled
CHM for T2DM & MetS
Not yet recruiting·HHong Kong Baptist University·N/A·NCT06450652·15 enrolled
A Phase 3 Study of HS-20094 in Patients With T2DM
Not yet recruiting·Jiangsu Hansoh Pharmaceutical Co., Ltd. logoJiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 3·NCT07156539·546 enrolled
A Study of LC542019 in Healthy Subjects and Subjects With T2DM
Completed·LLG Chem·Phase 1·NCT06333977·100 enrolled
Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan
Completed·UUniversity of Leicester·Phase 4·NCT02694263·25 enrolled
A Multi-center 12-week Study of HMS5552 in T2DM
Completed·HHua Medicine Limited·Phase 2·NCT02561338·258 enrolled
A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM
Completed·DDong-A ST Co., Ltd.·Phase 1·NCT03646721·108 enrolled
Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM
Completed·Sanofi logoSanofi·Phase 3·NCT02227212·40 enrolled
A Study of HS-20094 in T2DM Participants
Completed·Jiangsu Hansoh Pharmaceutical Co., Ltd. logoJiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 2·NCT06118008·54 enrolled
A Study of HS-20094 in Patients With T2DM
Completed·Jiangsu Hansoh Pharmaceutical Co., Ltd. logoJiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 2·NCT06901648·275 enrolled
Effect of HMP on Diabetic Microangiopaemia in T2DM
Completed·—·Phase 4·NCT05095922·40 enrolled
Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM
Completed·EElcelyx Therapeutics, Inc.·Phase 1/2·NCT01804842·26 enrolled
Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
Completed·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·Phase 1/2·NCT04466904·42 enrolled
Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM
Withdrawn·UUniversity of Maryland, Baltimore·N/A·NCT00732147
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)